A Review on Solubility Enhancement of Carvedilol—a BCS Class II Drug
- 31 Downloads
Carvedilol is a third generation non-cardioselective β-blocker used in the treatment of hypertension and demonstrated a potential in the treatment of cardiovascular diseases such as myocardial infarction and arrhythmias. For any drug to be therapeutically effective, it must enter the systemic circulation and to do so, it should have an optimum aqueous solubility at the site of absorption which is a major hurdle to overcome by a formulation scientist. Carvedilol belongs to BCS (biopharmaceutical classification system) class II drugs, thus having low solubility and poor bioavailability (around 25%). Hence, the purpose of this review is to elaborate on several approaches to increase the solubility, dissolution, and bioavailability of carvedilol.
Micronization, solid dispersions, cyclodextrin inclusion complex, hydrotropy, nanoformulation which include nanocrystals, nanosuspension, nanoemulsions, dendrimers, and polymeric nanoparticles. It also includes methods that have not been used on carvedilol such as cocrystallization and coamorphous technology.
Several approaches have successfully increased solubility and bioavailability of carvedilol and several other unexplored methods which have the potential to improve the aqueous solubility of carvedilol but have not been applied till date have also been discussed in the review.
There are various approaches explored to increase the solubility of carvedilol with every technique having certain advantages and drawbacks. Micronization and nanoformulations (dendrimers, nanoemulsion, nanosuspension, nanocrystals, polymeric nanoparticles) are the most widely used technique for solubility enhancement of carvedilol on laboratory scale due to higher solubility and dissolution rate but they have poor industrial applicability due to difficulty in scale-up and low yield. Efforts are being made to carry out different solubility enhancement techniques with good industrial applicability for carvedilol, e.g., cocrystals. Cocrystals and coamorphous approach for poorly soluble drugs having similar properties to carvedilol have shown good solubility, dissolution, and bioavailability compared to few techniques discussed in this review, and are being widely explored to overcome the drawbacks associated with its method of preparation by carrying out certain advancements (e.g., hot melt extrusion and sonocrystallization) to produce carvedilol cocrystals and coamorphous compound with unique properties in future development.
KeywordsSolubility enhancement Carvedilol Solid dispersion Cyclodextrin inclusion complex Nanosuspension Nanoemulsion Cocrystals
- 3.Savjani KT, Gajjar AK, Savjani JK. Drug solubility: importance and enhancement techniques. ISRN Pharm 2012;2012.Google Scholar
- 4.Kalimuthu S, Yadav AV. Formulation and evaluation of carvedilol loaded eudragit E100 nanoparticles. Int J PharmTech Res. 2009;1:179–83.Google Scholar
- 5.Jamakandi VG. Formulation and evaluation of immediate release tablet of carvedilol using liquisolid compacts technique for solubility enhancement. Asian J Pharm (AJP). 2016;10(03).Google Scholar
- 6.Campoli RD, Sorkin E. Carvedilol: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs. 1993;45:232–58.Google Scholar
- 7.Drugbank.ca. Carvedilol—DrugBank. 2017. [online] Available at: https://www.drugbank.ca/drugs/DB01136#pharmacology [Accessed 24 Jul 2017].
- 9.Zoghbi A, Wang B. Carvedilol solubility enhancement by inclusion complexation and solid dispersion. J Drug Deliv Ther. 2015;5(2):1–8.Google Scholar
- 10.Nollenberger, T. Using polymers to enhance solubility of poorly soluble drugs. 2017 [online] Pharmtech.com. Available at: http://www.pharmtech.com/using-polymers-enhance-solubility-poorly-soluble-drugs [Accessed 25 Jul 2017].
- 12.Chatterjee B, Pal TK. Development and in vitro evaluation of micronized sustained release matrix tablet of carvedilol. Int J Pharm Sci Res. 2010;1:96–102.Google Scholar
- 13.Mogal SA, Gurjar PN, Yamgar DS, Kamod AC. Solid dispersion technique for improving solubility of some poorly soluble drugs. Pharm Lett. 2012;4(5):1574–86.Google Scholar
- 14.Gala U, Pham H, Chauhan H. Pharmaceutical applications of eutectic mixtures. J Dev Drugs. 2013;2:1–2.Google Scholar
- 18.Ayoub M, Hasan A, El Nahas H, Ghazy FE. Enhancing oral bioavailability of carvedilol using solid dispersion technique. Int J Pharm Pharm Sci. 2016;8(7):193–9.Google Scholar
- 23.Chaudhary VB, Patel JK. Cyclodextrin inclusion complex to enhance solubility of poorly water-soluble drugs: a review. Int J Pharm Sci Res. 2013;4(1):68.Google Scholar
- 24.Vemula VR, Lagishetty V, Lingala S. Solubility enhancement techniques. Int J Pharm Sci Rev Res. 2010;5(1):41–51.Google Scholar
- 25.Chowdary KP, Kumar AP. Recent research on formulation development of BCS class II drugs—a review. Int Res J Pharm Appl Sci. 2013;3:173–81.Google Scholar
- 27.Patil JS, Kadam DV, Marapur SC, Kamalapur MV. Inclusion complex system: a novel technique to improve the solubility and bioavailability of poorly soluble drugs: a review. Int J Pharm Sci Rev Res. 2010;2(2):29–33.Google Scholar
- 28.Sapana BB, Shashikant DN. Preparation and characterisation of [beta]-cyclodextrin nebivolol inclusion complex. Int J Pharm Sci Res. 2015;6(5):2205.Google Scholar
- 30.Nidhi K, Indrajeet S, Khushboo M, Gauri K, Sen DJ. Hydrotropy: a promising tool for solubility enhancement: a review. Int J Drug Dev Res. 2011;Google Scholar
- 31.Chikhle H, Pandey V, Ganeshpurkar A, Dubey N, Bansal D. Solubility enhancement of carvedilol using mixed hydrotropy. Asian J Biomater Res. 2016;2(2):62–5.Google Scholar
- 37.Kulkarni SA, Myerson AS. Methods for crystals preparation. In Engineering Crystallography: From Molecule to Crystal to Functional Form 2017 (pp. 275–287). Springer, Dordrecht.Google Scholar
- 38.Gulsun T, Gursoy RN, Levent O. Nanocrystal technology for oral delivery of poorly water-soluble drugs. FABAD J Pharm Sci. 2009;7:34(5).Google Scholar
- 39.Janakiraman AK, Sumathi B, Saleem TM, Ramkanth S, Kumar PO, Venkatachalam G. Design and evaluation of carvedilol nanocrystals sustained release tablets. J Appl Pharm Sci. 2017;7(04):061–8.Google Scholar
- 41.Patil SK, Wagh KS, Parik VB, Akarte AM, Baviskar DT. Strategies for solubility enhancement of poorly soluble drugs. Int J Pharm Sci Rev Res. 2011;8(2):74–80.Google Scholar
- 44.Jasmina H, Džana O, Alisa E, Edina V, Ognjenka R. Preparation of nanoemulsions by high-energy and low energy emulsification methods. InCMBEBIH 2017 2017 (pp. 317–322). Springer, Singapore.Google Scholar
- 45.Chidi E, Ikenna NE, Zainab A, John F. Universal Journal of Pharmaceutical Research Development And Evaluation Of Nanoemulsion Formulations For Improved Oral Delivery Of Carvedilol. Univ J Pharm Res. 2017;2(1):2456–8058.Google Scholar
- 51.Mohanraj VJ, Chen Y. Nanoparticles—a review. Trop J Pharm Res. 2006;5(1):561–73.Google Scholar
- 52.Nagavarma BV, Yadav HK, Ayaz A, Vasudha LS, Shivakumar HG. Different techniques for preparation of polymeric nanoparticles—a review. Asian J Pharm Clin Res. 2012;5(3):16–23.Google Scholar
- 53.Khan S, Ali W, Rahman NU, Shah SM, Khan J, Shah SM, et al. Self-assembled biodegradable polymeric nanoparticles with improved solubility of carvedilol: preparation, characterisation and in vitro release kinetics. Int J Pharm Sci Res. 2016;7(10):3971.Google Scholar
- 54.Sanjay AN, Manohar SD, Bhanudas SR. Pharmaceutical cocrystallization: a review. J Adv Pharm Educ Res 2014;4(4).Google Scholar
- 55.Patole T, Deshpande A. Co-crystallization—a technique for solubility enhancement. Int J Pharm Sci Res. 2014;5(9):3566.Google Scholar
- 56.Jampílek J, Dohnal J. Investigation of carbohydrates and their derivatives as crystallization modifiers. InCarbohydrates-Comprehensive Studies on Glycobiology and Glycotechnology 2012. InTech.Google Scholar
- 57.Kotak U, Prajapati V, Solanki H, Jani G, Jha P. Co-crystallization technique its rationale and recent progress. World J Pharm Pharm Sci. 2015;4(4):1484–508.Google Scholar
- 58.Prasad RV, Rakesh MG, Jyotsna RM, Mangesh ST, Anita PS, Mayur PK. Pharmaceutical cocrystallization: a review. Int J Pharm Chem Sci. 2012;1(3):725–36.Google Scholar
- 59.Mounika P, Raj SV, Divya G, Gowramma A, Vijayamma G, Rangampet A, et al. Preparation and characterization of novel co-crystal forms of fexofenadine. Int J Innov Pharm Res. 2015;6(1):458–63.Google Scholar
- 61.(23b) Slurry crystallization of water-insoluble drug substance—overcoming challenges in solubility and miscibility requirements for solvents and anti-solvents | AIChE Academy [Internet]. Aiche.org. 2017 [Accesed on 7 Oct 2017]. Available from: https://www.aiche.org/conferences/aiche-annual-meeting/2012/proceeding/paper/23b-slurry-crystallization-water-insoluble-drug-substance-overcoming-challenges-solubility-and
- 65.Yadav S, Gupta PC, Sharma N, Kumar J. Cocrystals: an alternative approach to modify physicochemical properties of drugs. Int J Pharm Chem Biol Sci. 2015;5(2).Google Scholar
- 66.Sanjay AN, Manohar SD, Bhanudas SR. Pharmaceutical cocrystallization: a review. J Adv Pharm Educ Res 2014;4(4).Google Scholar
- 70.Chein W, Lamey K, Malofiy J, Oh C. Carvedilol formulations. WO 2003092625 A2, 2003Google Scholar
- 71.Oh C, Oh Choon K. Novel composition of carvedilol. United States patent application US 10/491,195. 2004 Oct 1.Google Scholar
- 72.Liversidge G, Jenkins S. Carvedilol phosphate solid dispersion. CA 2643492 A1, 2007.Google Scholar
- 73.Gary Liversidge, Scott Jenkins. Nanoparticle formulation of carvedilol. EP1996161A2, 2008Google Scholar
- 74.Parthasaradhi R, Rathnakar R, Muralidhara R, Subash C, Vamsi K. Carvedilol phosphate solid dispersion. WO 2014108921 A3, 2015.Google Scholar